From First Principles

Krishna Choudhary and Lester Nare

Destroying Tumors With Sound: Histotripsy with Dr. Zhen Xu

NOV 5, 202664 MIN

Description

Can sound destroy a tumor without an incision? Dr. Zhen Xu joins Krishna Choudhary to explain histotripsy: focused ultrasound that creates tiny bubbles to mechanically break apart tissue, without relying on heat. From a noise complaint in a University of Michigan lab to the Edison system, Xu traces the unexpected discovery, the physics of cavitation, and the decades of research behind noninvasive liver-tumor treatment. We explore surprising immune effects in animal studies, the #HOPE4LIVER clinical trials, and what remains to be tested for other organs. Recorded in Washington, D.C., on September 28, 2026, before the Golden Goose Awards ceremony. Xu is a histotripsy co-inventor, HistoSonics co-founder, and U-M's Li Ka Shing Professor of Biomedical Engineering. This is the first interview in our Golden Goose series. CHAPTERS 00:00 The discovery that became histotripsy 00:50 A PhD student and a heart problem 03:42 Heat vs. sound: how histotripsy works 07:06 Gas pockets, and why not the lungs 09:06 The first paper (2004) 09:38 "Don't read any papers": Yellow Pages and pig hearts 12:29 Too loud: rethinking the ultrasound pulse 14:56 "Almost like smoke": the 2002 discovery 18:14 Building the equipment, and the Edison system 22:19 Through the skull, and controlling the bubbles 23:50 The physics: pressure waves, bubbles and cells 28:47 Ten years to understand it 32:42 Surgery keeps getting smaller: from ether to Star Trek 35:58 The surprise: an immune response 38:16 Why liver cancer, and 9 of 11 rats 47:19 #HOPE4LIVER: the clinical trial 49:59 How a treatment works 52:27 Recovery and the 20-mile-run anecdote 56:24 The future: worldwide, kidney, pancreas and brain 1:01:33 The Golden Goose Award and federal funding 1:04:31 Sign-off 1:04:41 Outro RESEARCH & FURTHER READING First tissue-erosion paper (2004): https://doi.org/10.1109/tuffc.2004.1308731 High-speed imaging of bubble clouds (2007): https://doi.org/10.1109/tuffc.2007.504 Microtripsy and precise cavitation (2014): https://doi.org/10.1109/tuffc.2014.6722611 Bubble-cloud and cancer-cell interactions (2016): https://doi.org/10.1016/j.ultrasmedbio.2016.05.018 Histotripsy through the skull (2016): https://doi.org/10.1109/tuffc.2016.2531504 Abscopal immune responses: animal research (2020): https://doi.org/10.1136/jitc-2019-000200 Partial treatment of rat liver tumors (2022): https://doi.org/10.3390/cancers14071612 #HOPE4LIVER pivotal trial (2024): https://doi.org/10.1148/radiol.233051 #HOPE4LIVER one-year follow-up (2025): https://doi.org/10.1097/sla.0000000000006720 FDA Edison De Novo review: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN220087.pdf EDITORIAL NOTES 08:40 / 48:12: Edison received FDA De Novo authorization in 2023 for noninvasive liver-tumor destruction. This is not a general cancer-cure approval. 35:58-47:19: The cited immune-response and 9-of-11 results are animal studies, not human cure rates. 49:17: The one-year trial reported 63.4% local control on primary review and 90% on post hoc review. Technical success and durable tumor control are different measures. 53:46: The 20-mile run is an individual anecdote, not recovery advice; Dr. Xu explicitly advises against it. 55:39: The one-year #HOPE4LIVER update was published in 2025. Clinical and company updates reflect the September 2026 recording. Dr. Xu co-founded HistoSonics. WATCH & LISTEN Episode notes and research: https://ffppod.com/episodes/ep66 Golden Goose science rundown (EP59): https://ffppod.com/episodes/ep59 Watch and listen: https://ffppod.com Subscribe: https://www.youtube.com/@FromFirstPrinciplesPod?sub_confirmation=1 Support the show: https://ffppod.com/donate Follow @FFPPod on Instagram, TikTok, X and Facebook. Breaking down science news so it makes sense to curious people everywhere. #Histotripsy #GoldenGooseAward #SciencePodcast